Emergent BioSolutions

Contributing Author

Recent Articles by Emergent BioSolutions

Mar-03	Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors EBS GlobeNewswire
Feb-26	Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results EBS -26.58% EBS GlobeNewswire
Feb-26	Emergent BioSolutions Announces New $50 Million Stock Repurchase Program EBS -26.58% EBS GlobeNewswire
Feb-26	Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness EBS -26.58% EBS GlobeNewswire
Feb-12	Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN Nasal Spray Multipacks EBS GlobeNewswire
Feb-12	Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 EBS GlobeNewswire
Jan-14	Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness EBS GlobeNewswire
Jan-12	Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation EBS GlobeNewswire
Jan-08	Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026 EBS GlobeNewswire
Jan-08	Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa EBS GlobeNewswire
Jan-07	Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 EBS +5.70% GlobeNewswire
Dec-12	Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site EBS GlobeNewswire
Nov-18	Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access EBS GlobeNewswire
Nov-12	Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors EBS GlobeNewswire
Oct-29	Emergent BioSolutions Reports Third Quarter 2025 Financial Results EBS +36.60% EBS GlobeNewswire
Oct-28	Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness EBS GlobeNewswire
Oct-08	Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 EBS GlobeNewswire
Sep-24	Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone EBS +5.43% EBS GlobeNewswire
Sep-19	Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner EBS GlobeNewswire
Sep-15	Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain EBS GlobeNewswire
Sep-09	Emergent BioSolutions Receives New Contract Modification for ACAM2000, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness EBS +9.26% GlobeNewswire
Sep-02	Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use EBS GlobeNewswire
Aug-29	Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day EBS GlobeNewswire
Aug-27	Emergent BioSolutions to Participate in Upcoming Investor Conferences EBS GlobeNewswire
Aug-21	Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day EBS GlobeNewswire
Aug-06	Emergent BioSolutions Reports Second Quarter 2025 Financial Results EBS +36.65% EBS GlobeNewswire
Jul-28	New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox EBS -5.44% GlobeNewswire
Jul-28	Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives EBS -5.44% GlobeNewswire
Jul-15	Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 EBS -5.07% GlobeNewswire
Jul-08	Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts EBS +6.70% EBS GlobeNewswire
Jul-02	Emergent BioSolutions Expands NARCANDirect to Offer KLOXXADO (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate EBS +7.73% GlobeNewswire
Jun-23	Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Bolster U.S. Biodefense Supply EBS GlobeNewswire
Jun-20	Emergent BioSolutions Announces Addition to Russell 3000 Index EBS GlobeNewswire
Jun-05	Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies EBS GlobeNewswire
May-14	Emergent BioSolutions to Participate in Upcoming Investor Conferences EBS GlobeNewswire
May-07	Emergent BioSolutions Reports First Quarter 2025 Financial Results EBS +34.18% EBS GlobeNewswire
May-01	Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health EBS -7.87% GlobeNewswire

Emergent BioSolutions

Recent Articles by Emergent BioSolutions

Upgrade your FINVIZ experience